Samsung Bioepis Partners With Yuhan On Korean Adalimumab

Marketing Partnership Agreed For Adalloce Biosimilar Rival To Humira

 
• By Dave Wallace

Samsung Bioepis has added its Adalloce adalimumab version of Humira to its Korean biosimilars partnership with Yuhan Corporation, ahead of an imminent launch.

Korea Map Pin
Samsung Bioepis has extended its Korean partnership with Yuhan • Source: Shutterstock

Samsung Bioepis has expanded its biosimilars commercialization partnership with Yuhan Corporation in South Korea with the addition of its Adalloce (adalimumab) product, ahead of an imminent launch of the rival to AbbVie’s Humira.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business